The adjuvant treatment of HER2-positive breast cancer

Current Treatment Options in Oncology

Volumn 13, Issue 2, 2012, Pages 230-239

  Jelovac, Danijela ^a   Wolff, Antonio C ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adjuvant treatment; Breast cancer; HER2 positive breast cancer; Trastuzumab; Treatment

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; NAVELBINE; NERATINIB; PACLITAXEL; PERTUZUMAB; PLACEBO; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; DRUG TARGETING; DRUG WITHDRAWAL; EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; SIDE EFFECT; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOTOXINS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GENES, ERBB-2; HEART; HUMANS; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 84863719133     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-012-0186-4     Document Type: Article

References (40)

1. Berry DA, et al. Modeling the impact of treatment and screening on U.S. breast cancer mortality: A Bayesian approach. J Natl Cancer Inst Monogr, 2006 (36): P. 30-6.
2. Berry DA, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-92.
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2 (2):127-37.
4. Ross JS, et al. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14 (4):320-68.
5. Slamon DJ, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-12.
6. Slamon DJ, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82.
7. Wolff AC, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-45.
8. Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol. 2011;29(15):e458. Appropriate ER/PR and HER2 testing is the first step in the proper management of breast cancer patients. The Clinical Notice reconciles ER/PR and HER2 testing recommendations.
9. Konecny G, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95(2):142-53.
10. Menard S, et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol. 2001;19(2):329-35.
11. Thor AD, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90(18):1346-60.
12. Pritchard KI, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006;354(20):2103-11.
13. Cardoso F, et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-Alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol. 2004;24(1):201-9.
14. Villman K, et al. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Acta Oncol. 2006;45(5):590-6.
15. Konecny GE, et al. Her-2/neu gene amplification and response to paclitaxel in patients withmetastatic breast cancer. J Natl Cancer Inst. 2004;96(15):1141-51.
16. Hayes DF, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007;357 (15):1496-506.
17. Perez EA, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTGN9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366-73. This joint analysis of randomized NSABP B-31 and NCCTG N9831 showed improvement in DFS and OS in patients with HER2-positive breast cancer who received trastuzumab with anthracycline-based chemotherapy in adjuvant setting. These data provided support for use of trastuzumab as standard of care in adjuvant setting for patients with HER2-positive tumors 91cm.
18. Gianni L, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3):236-44. In contrast to NSABP B-31 and NCCTG N9831, in HERA trial patients who completed adjuvant chemotherapy and radiation therapy, were randomized to trastuzumab for one or two years, or no additional therapy. Patients on arm treated with trastuzumab for one year had significantly improved DFS compared with arm without trastuzumab.
19. Slamon D, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365 (14):1273-83. Results from this randomized trial indicate that trastuzumab plus non-Anthracycline chemotherapy is reasonable and effective alternative to anthracycline-based regimen with improved toxicity profile in adjuvant setting for patients with HER2-positive disease.
20. Joensuu H, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial. J Clin Oncol. 2009;27(34):5685-92. All of the previously described trials used adjuvant trastuzumab for at least one year. The FinHER trial tested shorter course of trastuzumab. Even with short course of trastuzumab patients tended to have better DFS than those treated with chemotherapy only.
21. Perez EA, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011;29(34):4491-7.
22. Spielmann M, et al. Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009;27 (36):6129-34.
23. Dang C, et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol. 2008;26(8):1216-22.
24. Gonzalez-Angulo AM, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, nodenegative tumors 1 cm or smaller. J Clin Oncol. 2009;27(34):5700-6.
25. Curigliano G, et al. Clinical relevance of HER2 overexpression/ amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol. 2009;27(34):5693-9.
26. Hayes DF, Picard MH. Heart of darkness: The downside of trastuzumab. J Clin Oncol. 2006;24 (25):4056-8.
27. Perez EA, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26(8):1231-8.
28. Russell SD, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: A combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010;28(21):3416-21.
29. Hurvitz S.et al. Final results of a Phase II trial evaluating trastuzumab and bevacizumab as first line treatment in HER2-Amplified advanced breast cancer. San Antonio Breast Cancer Symposium; Abstract 6094, 2009.
30. Goss P, et al. Results of a randomized, double-blind, multicenter, placebo controlled study of adjuvant lapatinib in women with early-stage Erb2-overexpressing braeast cancer. San Antonio Breast Cancer Symposium., 2011.
31. Buzdar AU, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23(16):3676-85.
32. Chang J, et al. TBCRC 006: A multicenter phase II of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. J Clin Oncol; suppl, 2011. 29: P. Abstract #505.
33. Untch M, Lapatinib versus Trastuzumab in Combination with Neoadjuvant Antracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO STUDY (GBG 44). Cancer Research Supp, 2010. 70: P. 81s.
34. Gianni L, et al. Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II (NeoSphere). Cancer Research Supp, 2010. 70: P. 82s.
35. Baselga, J.et al. First results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in women with HER2-Positive Primary Breast Cancer. Cancer Research Supp, 2010. 70: P. 82s
36. Adams CW, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother. 2006;55(6):717-27.
37. Baselga J, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-19.
38. Lewis Phillips GD, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibodycytotoxic drug conjugate. Cancer Res. 2008;68 (22):9280-90.
39. Burris 3rd HA, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29 (4):398-405.
40. Perez E, et al. Efficacy and Safety of Trastuzumab-DM1 Versus Trastuzumab plus Docetaxel in HER2-Positive Metastatic Breast Cancer Patients with No Prior Chemotherapy for Metastatic Disease: Preliminary results of a Randomized, Multicenter, Open-Label Phase 2 Study. 35th Congress of the European Society of Medical Oncology, 2010.